hsa-mir-1298: Hsa-mir-1298 is a microRNA gene located on the X chromosome (Xq23) and is 112 bases in length [PMC8006078]. It has been predicted to target DROSHA by the Patrocles and TargetScan prediction algorithms [PMC4229095]. However, a single nucleotide polymorphism (SNP) called rs10719 in the 3' untranslated region (UTR) of DROSHA is predicted to abolish the binding site of hsa-mir-1298 [PMC4229095]. Hsa-mir-1298 has been associated with improved survival in patients, along with hsa-miR-122 and hsa-miR-200 [PMC10093233]. LncRNA-RP11-583F2.2 has been identified as a competing endogenous RNA (ceRNA) targeting hsa-mir-1298 through the lncRBA database [PMC7324892]. Bioinformatics analysis has identified hsa-mir-1298 and lncRNA-RP11-583F2.2 as promising non-coding RNAs relevant to hepatocellular carcinoma (HCC) based on microarray studies and clinical validation in HCC patients versus controls [PMC7324892]. Pathway enrichment analysis has revealed that hsa-mir-1298 is associated with target genes related to carcinogenesis, exosome secretion, apoptosis, and cell adhesion through the Diana database [PMC7324892]. Hsa-circ_0078383 is targeted by multiple miRNAs including hsa-mir-1298 [PMC8483823]. In a study focusing on neural cell-type-specific response, hsa-mir-1298 was found to be significantly up-regulated in Hypr-infected neurons but down-regulated in Hypr-infected astrocytes [PMC9167876]. Among the predicted mRNA targets of hsa-mir-1298, RSAD2 and CMPK2 were identified as the most important, as they have been documented to interfere with flavivirus infection [PMC9167876].